BRIEF-Revive Therapeutics announces rights offering to fund clinical development of Bucillamine

Mon May 16, 2016 7:24am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

May 16 (Reuters) - Revive Therapeutics Ltd

* Revive announces rights offering to fund the clinical development of Bucillamine for the treatment of Cystinuria Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)